Answers are grounded in this paper and cite their sources.
Double antibody sandwich ELISA revealed pharmacokinetics of rh-IFN-2a-NGR in different animals, suggesting its potential for tumor targeted-therapy.
The compound rh-IFN -2a-NGR can inhibit tumor angiogenesis and could be used for targeted therapy. In the present study, double antibody sandwich ELISA analysis was used to determine the concentration of rhIFN -2a-NGR in serum after intramuscular administration of various dosages to mice, rats and monkeys. The results showed that the pharmacokinetic properties of rh-IFN 2a-NGR after i. m. administration to mice, rats and monkeys were consistent with a one-compartment open model. The main pharmacokinetic parameters in mice (9.36 μg/kg), rats (4.68 μg/kg) and monkeys (2.34 μg/kg) after i.m. rh-IFNα2a-NGR were as follows: Tpeak was 0.49, 1.65 and 3.60 h, Cmax was 3030.20, 654.49 and 268.13 ng/L, t1/2 was 0.39, 4.52 and 2.70 h, and AUC(0-∞) was 4197.65, 5784.58 and 2622.06 ng/L·h, respectively. Also, mice, rats and monkeys had their own distinct metabolic characteristics. These data would provide references for further clinical pharmacokinetic study of rh-IFNα2a-NGR.
No takes yet. Share an insight, caveat, or question.
Li et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: